Rep. David Taylor (R-OH) Buys Medpace (MEDP) Stock
Congressman David Taylor bought shares of Medpace Holdings valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. David Taylor (R-OH) bought between $1,001 and $15,000 of Medpace Holdings, Inc. ($MEDP) stock on May 15, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed May 28, 2026.
Since the trade, $MEDP is up 4.2% after 1 week, up 12.6% after 1 month and up 48.9% to date (from the $415.27 close on May 15, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. David Taylor (R-OH)
- Status:
- Member — House
- State/District:
- OH-2
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- May 28, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Medpace Holdings, Inc. ($MEDP) | Buy | May 15, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
MEDP
Medpace Holdings, Inc.
Key Points
- David Taylor, a Republican representative from Ohio's 2nd district, purchased shares of Medpace Holdings, Inc. valued between $1,001 and $15,000 on May 15, 2026.
- Shares of Medpace are currently at $512.79, down from a previous close of $616.63, which could signal potential interest from investors given the recent activity.
- Analysts have a consensus rating of 'hold' for Medpace, with a mean price target of about $595.92.
Get $MEDP trade alerts by text
We text you when insiders, Congress or big funds trade $MEDP. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Medpace Holdings, Inc. alert may contain errors. Disclosures
Lawmaker's Recent Trade
On May 15, 2026, Congressman David Taylor, a Republican from Ohio's 2nd district, bought shares in Medpace Holdings, Inc. (NASDAQ: MEDP). The transaction, valued between $1,001 and $15,000, was reported on May 28, 2026. This purchase adds to Taylor's recent investment activity in various companies, indicating his continued engagement in the stock market.
David Taylor vs. the S&P 500
Hypothetical returns from David Taylor's disclosed trades, not real profit or advice. How we model this.
Prior Trading Activity
This isn't the first time David Taylor has made headlines with his stock trades. On June 5, 2026, he disclosed purchases of shares in several companies, including The Kroger Co., Amgen Inc., and American Electric Power, all valued between $1,001 and $15,000. These trades reflect Taylor's diverse investment strategy and ongoing interest in both consumer and healthcare sectors.
Medpace Stock Performance
Currently, Medpace's shares are trading at $512.79, a decline from the previous close of $616.63. This stock has ranged between $373.00 and $677.90 over the past year, suggesting volatility. While Taylor’s purchase is modest, it shows confidence in a company whose services are crucial in the healthcare industry, especially as it continues to grow.
Analysts Set New Price Targets
Analysts have mixed views on Medpace. On October 7, 2026, Mizuho maintained an 'Outperform' rating with a price target raised to $700. Meanwhile, Barclays kept an 'Equal-Weight' rating with a target of $625. UBS upgraded its rating to 'Neutral' with a target of $673 on September 30, 2026. Currently, analysts have a consensus rating of 'hold' for Medpace, with a mean price target of approximately $595.92.
What Medpace Holdings, Inc. Does
Medpace Holdings, Inc. provides clinical research services for drug and medical device development across several continents. Founded in 1992 and based in Cincinnati, Ohio, it has grown to serve a vital role in the healthcare sector, particularly in supporting the clinical development process for pharmaceuticals and biotechnology.
What's Ahead for Medpace Holdings, Inc.
Investors will be watching for Medpace's next earnings report scheduled for October 21, 2026. Taylor's purchase adds to a series of trades that may reflect broader confidence in the company and its industry. As the market evolves, it will be interesting to see how Taylor’s investments develop, especially in light of his recent trading patterns.
Related Filing Alerts
Source: David Taylor's STOCK Act disclosure on $MEDP (May 15, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts